The Big Picture: Let’s face it: HIPAA is inevitableBy Kathy Kincade, EditorI have this bad habit. When it comes to certain tasks, such as paying bills or cleaning the bathroom or taking my (almost daily) walk/run, I can find numerous ways
By Kathy Kincade, Editor
I have this bad habit. When it comes to certain tasks, such as paying bills or cleaning the bathroom or taking my (almost daily) walk/run, I can find numerous ways to delay the inevitable. I consider this masterful multitasking; others call it procrastination.
It is one thing to do this in your personal life, quite another to let it creep into your work. Like many jobs, publishing is built on deadlines. Making them is paramount; missing them can be costly.
The problem is, there always seems to be so much timeuntil, of course, the deadline is tomorrow. Then you scratch your head and wonder where the days went.
When it comes to the new HIPAA regulations, timing is everything. Although most of the proposed rules will be finalized by the first of the year, the deadline for complying with them is still at least two years away. For many vendors, this puts HIPAA on the back burner for the time being.
But product cycles can be long, and what is on the drawing board today is likely to become reality about the time HIPAA finally takes effect. Delaying the inevitable will only make things harderand more expensivein the long run. If you are not doing so already, take a serious look at your products data security and transaction options. Consider the standards you already comply with, and others on which you need to get up to speed. Talk to your customers data-security specialists, not just the radiology managers or CIOs.
Trust mecome 2002, youll be glad you did.
Comparative AI Study Shows Merits of RapidAI LVO Software in Stroke Detection
February 6th 2025The Rapid LVO AI software detected 33 percent more cases of large vessel occlusion (LVO) on computed tomography angiography (CTA) than Viz LVO AI software, according to a new comparative study presented at the International Stroke Conference (ISC).
What a New Meta-Analysis Reveals About PET/CT Radiotracers for csPCa
February 6th 2025The PET/CT agent 18F-PSMA-1007 offered the highest surface under the cumulative ranking curve (SUCRA) out of nine radiotracers at the patient and lesion level for detecting clinically significant prostate cancer (csPCa), according to a meta-analysis.